ANTX - AN2 Therapeutics, Inc.

1.25
0.010   0.800%

Share volume: 180,450
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$1.24
0.01
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
26%
Profitability 0%
Dept financing 10%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.57%
1 Month
-7.41%
3 Months
0   0%
6 Months
20.19%
1 Year
-59.02%
2 Year
-86.11%
Key data
Stock price
$1.25
P/E Ratio 
0.00
DAY RANGE
$1.24 - $1.33
EPS 
-$1.72
52 WEEK RANGE
$0.87 - $3.12
52 WEEK CHANGE
-$58.88
MARKET CAP 
41.233 M
YIELD 
N/A
SHARES OUTSTANDING 
29.842 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
2.88
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$88,811
AVERAGE 30 VOLUME 
$89,708
Company detail
CEO: Eric Easom
Region: US
Website: an2therapeutics.com
Employees: 20
IPO year: 2022
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

AN2 Therapeutics is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Recent news
loading